|
JP4394279B2
(ja)
*
|
1998-03-09 |
2010-01-06 |
ジーランド ファーマ アクティーゼルスカブ |
酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US7550425B2
(en)
|
2000-06-16 |
2009-06-23 |
Zealand Pharma A/S |
Diuretic peptide conjugates
|
|
DK1737889T3
(da)
|
2004-10-19 |
2011-01-03 |
Lonza Ag |
Fremgangsmåde til fastfase-peptidsyntese
|
|
SI1877435T2
(sl)
|
2005-05-04 |
2021-05-31 |
Zealand Pharma A/S |
Analogi glukagonu podobnega peptida-2(GLP-2)
|
|
GB0514071D0
(en)
|
2005-07-07 |
2005-08-17 |
Zealand Pharma As |
N- or C- terminally modified small peptides
|
|
EP1975142A4
(en)
*
|
2005-11-22 |
2009-12-02 |
Univ Nihon |
AUTOMATED SOLID PHASE SYNTHESIS OF PYRROL-IMIDAZOLE POLYAMIDE
|
|
SG170767A1
(en)
|
2005-12-23 |
2011-05-30 |
Zealand Pharma As |
Modified lysine-mimetic compounds
|
|
WO2007097561A1
(en)
*
|
2006-02-20 |
2007-08-30 |
Ewha University - Industry Collaboration Foundation |
Peptide having cell membrane penetrating activity
|
|
KR101462454B1
(ko)
*
|
2006-03-29 |
2014-11-17 |
가부시키가이샤 도우사 고가쿠 겐큐쇼 |
펩티드의 티오에스테르 화합물의 제조 방법
|
|
EP2051995B1
(en)
|
2006-11-08 |
2017-02-08 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (glp-2) analogues
|
|
DK2158214T3
(da)
|
2007-06-15 |
2011-12-05 |
Zealand Pharma As |
Glukagonanaloger
|
|
JP5635529B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
JP5635531B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
WO2010070252A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
|
NZ593813A
(en)
|
2008-12-15 |
2013-02-22 |
Zealand Pharma As |
Glucagon analogues
|
|
ME02220B
(me)
|
2009-07-13 |
2016-02-20 |
Zealand Pharma As |
Analozi acilovanog glukagona
|
|
SG184988A1
(en)
|
2010-04-27 |
2012-11-29 |
Zealand Pharma As |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
EP2585482B1
(en)
|
2010-06-24 |
2019-03-27 |
Zealand Pharma A/S |
Glucagon analogues
|
|
MA34913B1
(fr)
|
2011-01-20 |
2014-02-01 |
Zealand Pharma As |
Combinaison d'analogues du glucagon acylé à des analogues d'insuline
|
|
CA2853884A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
|
SG11201403377QA
(en)
|
2011-12-23 |
2014-07-30 |
Zealand Pharma As |
Glucagon analogues
|
|
WO2013098408A1
(en)
|
2011-12-30 |
2013-07-04 |
Zealand Pharma A/S |
Glucagon and cck receptor agonist peptide conjugates
|
|
AR089860A1
(es)
|
2012-02-03 |
2014-09-24 |
Zealand Pharma As |
Analogos de la grelina
|
|
WO2013164483A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
KR20150006052A
(ko)
|
2012-05-03 |
2015-01-15 |
질랜드 파마 에이/에스 |
글루카곤-유사 펩타이드-2 (ｇｌｐ-2) 유사체
|
|
MY170671A
(en)
|
2012-07-23 |
2019-08-26 |
Zealand Pharma As |
Glucagon analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
EP2970487B1
(en)
|
2013-03-12 |
2020-03-11 |
Molecular Templates, Inc. |
Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
|
|
US9169287B2
(en)
|
2013-03-15 |
2015-10-27 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
US9695214B2
(en)
|
2013-03-15 |
2017-07-04 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
ES2623979T3
(es)
|
2013-03-21 |
2017-07-12 |
Sanofi-Aventis Deutschland Gmbh |
Síntesis de productos peptídicos que contienen hidantoína
|
|
ES2624961T3
(es)
|
2013-03-21 |
2017-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Síntesis de productos de péptido que contienen imida cíclica
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
SI3057984T1
(sl)
|
2013-10-17 |
2018-10-30 |
Zealand Pharma A/S |
Acilirani glukagonski analogi
|
|
US10093713B2
(en)
|
2013-11-06 |
2018-10-09 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
EA035688B1
(ru)
|
2013-11-06 |
2020-07-27 |
Зилэнд Фарма А/С |
Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
|
|
US10435474B2
(en)
|
2013-12-24 |
2019-10-08 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
KR20160113158A
(ko)
|
2014-01-27 |
2016-09-28 |
몰레큘러 템플레이츠, 인코퍼레이션. |
폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
|
|
WO2015138435A1
(en)
|
2014-03-11 |
2015-09-17 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
|
EP3872090A1
(en)
|
2014-03-11 |
2021-09-01 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
|
US10815469B2
(en)
|
2014-06-11 |
2020-10-27 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
|
|
CA2953569A1
(en)
|
2014-06-26 |
2015-12-30 |
Ossianix, Inc. |
Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
|
|
TWI705973B
(zh)
|
2014-10-29 |
2020-10-01 |
丹麥商西蘭製藥公司 |
Ｇｉｐ促效劑化合物及方法
|
|
EP3218411B1
(en)
|
2014-11-14 |
2022-01-12 |
Ossianix, Inc. |
Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
|
|
JP6444486B2
(ja)
|
2015-02-05 |
2018-12-26 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
志賀毒素ａサブユニットエフェクター領域を含む多価ｃｄ２０結合分子及びそれらの強化組成物
|
|
CN107567459B
(zh)
|
2015-03-18 |
2021-09-24 |
西兰制药公司 |
胰淀素类似物
|
|
GB201506380D0
(en)
|
2015-04-15 |
2015-05-27 |
Serodus Asa |
Materials and methods for treatment of pulmonary hypertension
|
|
TWI707867B
(zh)
|
2015-04-16 |
2020-10-21 |
丹麥商西蘭製藥公司 |
醯化之昇糖素類似物
|
|
JP6771492B2
(ja)
|
2015-05-30 |
2020-10-21 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
|
|
MX2018001208A
(es)
|
2015-07-26 |
2018-03-26 |
Molecular Templates Inc |
Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
|
|
CN108290923A
(zh)
*
|
2015-09-17 |
2018-07-17 |
麻省理工学院 |
用于固相肽合成的方法和系统
|
|
WO2018031424A1
(en)
|
2016-08-06 |
2018-02-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
TWI784968B
(zh)
|
2016-09-09 |
2022-12-01 |
丹麥商西蘭製藥公司 |
澱粉素類似物
|
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018104561A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
CN110099922A
(zh)
|
2016-12-09 |
2019-08-06 |
西兰制药公司 |
Glp-1/glp-2双重激动剂
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
DK3881861T3
(da)
|
2017-06-16 |
2024-09-09 |
Zealand Pharma As |
Doseringsregimer for indgivelse af glukagonlignende peptid-2- (GLP-2)-analoger
|
|
CA3080351A1
(en)
|
2017-11-02 |
2019-05-09 |
Ossianix, Inc. |
Improved tfr-selective binding peptides capable of crossing the blood brain barrier
|
|
AU2019228639A1
(en)
|
2018-02-27 |
2020-09-17 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
|
MX2019009726A
(es)
|
2018-04-17 |
2020-02-05 |
Molecular Templates Inc |
Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
|
|
US12258414B2
(en)
|
2018-06-22 |
2025-03-25 |
Ossianix, Inc. |
Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
|
|
CN112218877B
(zh)
|
2018-08-27 |
2025-07-25 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
WO2020056327A1
(en)
|
2018-09-14 |
2020-03-19 |
Ossianix, Inc. |
Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
WO2020154531A1
(en)
|
2019-01-23 |
2020-07-30 |
Millennium Pharmaceuticals, Inc. |
Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
|
|
EP3914358A1
(en)
|
2019-01-23 |
2021-12-01 |
Millennium Pharmaceuticals, Inc. |
Anti-cd38 antibodies
|
|
CA3138715A1
(en)
|
2019-06-14 |
2020-12-17 |
Zealand Pharma A/S |
Pharmaceutical parenteral composition of dual glp1/2 agonist
|
|
ES3049784T3
(en)
|
2019-08-27 |
2025-12-18 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
|
US11918649B2
(en)
|
2019-09-18 |
2024-03-05 |
Molecular Templates, Inc. |
PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
|
|
CA3155089A1
(en)
|
2019-09-20 |
2021-03-25 |
Zealand Pharma A/S |
Kv1.3 blockers
|
|
US20210155671A1
(en)
|
2019-11-24 |
2021-05-27 |
Molecular Templates, Inc. |
Uses of cd20-binding molecules and additional therapeutic agents
|
|
US20230129788A1
(en)
|
2020-03-30 |
2023-04-27 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
US20230110689A1
(en)
|
2020-03-30 |
2023-04-13 |
Zealand Pharma A/S |
Agonist combination
|
|
IL299870A
(en)
|
2020-07-16 |
2023-03-01 |
Zp Spv 3 K/S |
Complement factor C3 inhibitors and their medical uses
|
|
WO2022103769A1
(en)
|
2020-11-11 |
2022-05-19 |
Ossianix, Inc. |
High affinity human and monkey specific tfr-1 vnars
|
|
IL301891A
(en)
|
2020-12-16 |
2023-06-01 |
Zealand Pharma As |
Drug composition of dual GLP-1/GLP-2 agonists
|
|
EP4262745B1
(en)
|
2020-12-16 |
2025-01-29 |
Zealand Pharma A/S |
Pharmaceutical composition of glp-1/glp-2 dual agonists
|
|
JP7751641B2
(ja)
|
2020-12-16 |
2025-10-08 |
ジーランド ファーマ エー／エス |
Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
|
|
US20240316155A1
(en)
|
2021-02-18 |
2024-09-26 |
Zealand Pharma A/S |
Composition for treating short bowel syndrome
|
|
EP4308242A1
(en)
|
2021-03-17 |
2024-01-24 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
|
MX2023010930A
(es)
|
2021-03-23 |
2023-09-28 |
Zealand Pharma As |
Bloqueadores de kv1.3.
|
|
WO2022260877A1
(en)
|
2021-06-07 |
2022-12-15 |
Ossianix, Inc. |
Shark vnars for treating covid-19
|
|
US20240279298A1
(en)
|
2021-06-18 |
2024-08-22 |
Beijing Tuo Jie Biopharmaceutical Co. Ltd. |
Glucagon analog and medical use thereof
|
|
US20250122298A1
(en)
|
2021-08-17 |
2025-04-17 |
Ossianix, Inc. |
Deimmunized vnar domains and scaffolds
|
|
CA3228429A1
(en)
|
2021-09-03 |
2023-03-09 |
Mikkel Askjar Agersnap |
Dosage regime
|
|
IL313185A
(en)
|
2021-12-01 |
2024-07-01 |
Zealand Pharma As |
Peptide inhibitors of the interleukin-23 receptor
|
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
|
CN120265307A
(zh)
|
2022-10-18 |
2025-07-04 |
西兰制药公司 |
抑制剂
|
|
WO2024168411A1
(pt)
*
|
2023-02-15 |
2024-08-22 |
Proteimax Bio Technology Israel Ltd |
Aditivo de alimento e/ou suplemento alimentar, processo de obtenção, formulação de alimento funcional e/ou suplemento alimentar, uso
|
|
EP4471049A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
EP4471048A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
WO2025056677A1
(en)
|
2023-09-15 |
2025-03-20 |
Zealand Pharma A/S |
Dasiglucagon for use in the treatment of congenital hyperinsulinism
|
|
TW202530247A
(zh)
|
2023-12-04 |
2025-08-01 |
丹麥商西蘭製藥公司 |
方法
|
|
TW202528338A
(zh)
|
2023-12-04 |
2025-07-16 |
丹麥商西蘭製藥公司 |
方法
|
|
WO2025248124A1
(en)
|
2024-05-31 |
2025-12-04 |
Zealand Pharma A/S |
Dapiglutide for use in treating a sub-group of subjects
|
|
US20250381242A1
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Antimicrobial peptides against citrus greening
|
|
WO2025259842A2
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Novel alpha-factor based peptides with antifungal activity
|
|
WO2025262301A1
(en)
|
2024-06-20 |
2025-12-26 |
Zealand Pharma A/S |
Petrelintide for use in the treatment of obesity, diabetes or a disease linked to obesity or diabetes, or of reducing body weight, inhibiting weight gain or reducing food intake
|
|
WO2026003546A1
(en)
|
2024-06-27 |
2026-01-02 |
Vrg Miniprotein Zrt |
Potassium ion kv1.3 channel inhibitors
|
|
WO2026013260A1
(en)
|
2024-07-12 |
2026-01-15 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
WO2026052859A1
(en)
|
2024-09-09 |
2026-03-12 |
Zealand Pharma A/S |
Treatment with dapiglutide
|
|
WO2026052861A1
(en)
|
2024-09-09 |
2026-03-12 |
Zealand Pharma A/S |
Treatment with dapiglutide
|